Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323652806> ?p ?o ?g. }
- W4323652806 abstract "Abstract Background Chronic kidney disease (CKD) patients with and without heart failure (HF) often present with hyperkalaemia (HK) leading to increased risk of hospitalisations, cardiovascular related events and cardiovascular-related mortality. Renin–angiotensin–aldosterone system inhibitor (RAASi) therapy, the mainstay treatment in CKD management, provides significant cardiovascular and renal protection. Nevertheless, its use in the clinic is often suboptimal and treatment is frequently discontinued due to its association with HK. We evaluated the cost-effectiveness of patiromer, a treatment known to reduce potassium levels and increase cardiorenal protection in patients receiving RAASi, in the UK healthcare setting. Methods A Markov cohort model was generated to assess the pharmacoeconomic impact of patiromer treatment in regulating HK in patients with advanced CKD with and without HF. The model was generated to predict the natural history of both CKD and HF and quantify the costs and clinical benefits associated with the use of patiromer for HK management from a healthcare payer’s perspective in the UK. Results Economic evaluation of patiromer use compared to standard of care (SoC) resulted in increased discounted life years (8.93 versus 8.67) and increased discounted quality-adjusted life years (QALYs) (6.36 versus 6.16). Furthermore, patiromer use resulted in incremental discounted cost of £2,973 per patient and an incremental cost-effectiveness ratio (ICER) of £14,816 per QALY gained. On average, patients remained on patiromer therapy for 7.7 months, and treatment associated with a decrease in overall clinical event incidence and delayed CKD progression. Compared to SoC, patiromer use resulted in 218 fewer HK events per 1,000 patients, when evaluating potassium levels at the 5.5–6 mmol/l; 165 fewer RAASi discontinuation episodes; and 64 fewer RAASi down-titration episodes. In the UK, patiromer treatment was predicted to have a 94.5% and 100% chance of cost-effectiveness at willingness-to-pay thresholds (WTP) of £20,000/QALY and £30,000/QALY, respectively. Conclusion This study highlights the value of both HK normalisation and RAASi maintenance in CKD patients with and without HF. Results support the guidelines which recommend HK treatment, e.g., patiromer, as a strategy to enable the continuation of RAASi therapy and improve clinical outcomes in CKD patients with and without HF." @default.
- W4323652806 created "2023-03-10" @default.
- W4323652806 creator A5011697322 @default.
- W4323652806 creator A5020075219 @default.
- W4323652806 creator A5023339429 @default.
- W4323652806 creator A5062979710 @default.
- W4323652806 creator A5077989735 @default.
- W4323652806 date "2023-03-09" @default.
- W4323652806 modified "2023-10-06" @default.
- W4323652806 title "A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure" @default.
- W4323652806 cites W115306065 @default.
- W4323652806 cites W1540166912 @default.
- W4323652806 cites W1756552807 @default.
- W4323652806 cites W1844902057 @default.
- W4323652806 cites W1973622329 @default.
- W4323652806 cites W1979142749 @default.
- W4323652806 cites W1982802704 @default.
- W4323652806 cites W1993257960 @default.
- W4323652806 cites W2007720170 @default.
- W4323652806 cites W2007975660 @default.
- W4323652806 cites W2021012510 @default.
- W4323652806 cites W2021566270 @default.
- W4323652806 cites W2032220099 @default.
- W4323652806 cites W2045758472 @default.
- W4323652806 cites W2052349502 @default.
- W4323652806 cites W2055123579 @default.
- W4323652806 cites W2085301914 @default.
- W4323652806 cites W2096101576 @default.
- W4323652806 cites W2102732068 @default.
- W4323652806 cites W2103679597 @default.
- W4323652806 cites W2112353268 @default.
- W4323652806 cites W2113117011 @default.
- W4323652806 cites W2116034528 @default.
- W4323652806 cites W2118580313 @default.
- W4323652806 cites W2119768791 @default.
- W4323652806 cites W2135659723 @default.
- W4323652806 cites W2141343169 @default.
- W4323652806 cites W2145632027 @default.
- W4323652806 cites W2150933235 @default.
- W4323652806 cites W2152271789 @default.
- W4323652806 cites W2163340573 @default.
- W4323652806 cites W2165262170 @default.
- W4323652806 cites W2170453602 @default.
- W4323652806 cites W2170682979 @default.
- W4323652806 cites W2182000067 @default.
- W4323652806 cites W2207247573 @default.
- W4323652806 cites W2310295517 @default.
- W4323652806 cites W2319308197 @default.
- W4323652806 cites W2324948948 @default.
- W4323652806 cites W2337220738 @default.
- W4323652806 cites W2418170045 @default.
- W4323652806 cites W2427094903 @default.
- W4323652806 cites W2588389730 @default.
- W4323652806 cites W2650906489 @default.
- W4323652806 cites W2751931046 @default.
- W4323652806 cites W2768859679 @default.
- W4323652806 cites W2803591266 @default.
- W4323652806 cites W2888038580 @default.
- W4323652806 cites W2889536718 @default.
- W4323652806 cites W2925157573 @default.
- W4323652806 cites W2930580009 @default.
- W4323652806 cites W2931650530 @default.
- W4323652806 cites W2941516707 @default.
- W4323652806 cites W2972966903 @default.
- W4323652806 cites W2985892893 @default.
- W4323652806 cites W3003939618 @default.
- W4323652806 cites W3010053023 @default.
- W4323652806 cites W3023215543 @default.
- W4323652806 cites W3086387464 @default.
- W4323652806 cites W3129835379 @default.
- W4323652806 cites W3135968252 @default.
- W4323652806 cites W3195993230 @default.
- W4323652806 cites W4244292213 @default.
- W4323652806 cites W4289780611 @default.
- W4323652806 cites W43173900 @default.
- W4323652806 cites W4317871049 @default.
- W4323652806 doi "https://doi.org/10.1186/s12882-023-03088-3" @default.
- W4323652806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36890464" @default.
- W4323652806 hasPublicationYear "2023" @default.
- W4323652806 type Work @default.
- W4323652806 citedByCount "2" @default.
- W4323652806 countsByYear W43236528062023 @default.
- W4323652806 crossrefType "journal-article" @default.
- W4323652806 hasAuthorship W4323652806A5011697322 @default.
- W4323652806 hasAuthorship W4323652806A5020075219 @default.
- W4323652806 hasAuthorship W4323652806A5023339429 @default.
- W4323652806 hasAuthorship W4323652806A5062979710 @default.
- W4323652806 hasAuthorship W4323652806A5077989735 @default.
- W4323652806 hasBestOaLocation W43236528061 @default.
- W4323652806 hasConcept C126322002 @default.
- W4323652806 hasConcept C164705383 @default.
- W4323652806 hasConcept C177713679 @default.
- W4323652806 hasConcept C2778198053 @default.
- W4323652806 hasConcept C2778653478 @default.
- W4323652806 hasConcept C71924100 @default.
- W4323652806 hasConcept C72563966 @default.
- W4323652806 hasConceptScore W4323652806C126322002 @default.
- W4323652806 hasConceptScore W4323652806C164705383 @default.
- W4323652806 hasConceptScore W4323652806C177713679 @default.
- W4323652806 hasConceptScore W4323652806C2778198053 @default.